Literature DB >> 6384785

The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study.

C L Sprung, P V Caralis, E H Marcial, M Pierce, M A Gelbard, W M Long, R C Duncan, M D Tendler, M Karpf.   

Abstract

To determine whether corticosteroids are efficacious in severe septic shock, we conducted a prospective study of 59 patients randomly assigned to a methylprednisolone, dexamethasone, or control group. Patients were treated 17.5 +/- 5.4 hours (mean +/- S.E.M.) after the onset of shock, and 55 patients required vasopressor agents. Early in the hospital course, reversal of shock was more likely in patients who received corticosteroids than in those who did not. Four (19 per cent) of 21 methylprednisolone-treated, 7 (32 per cent) of 22 dexamethasone-treated, and none of 16 control patients had reversal of shock 24 hours after drug administration (corticosteroid groups vs. control group, P less than 0.05). Patients treated with corticosteroids within four hours after the onset of shock had a higher incidence of shock reversal (P less than 0.05). At 133 hours after drug administration, 17 (40 per cent) of 43 corticosteroid-treated patients had died, and 11 (69 per cent) of 16 control patients had died (P less than 0.05). However, these differences in reversal of shock and survival disappeared later in the course. Overall, 16 (76 per cent) of 21 patients receiving methylprednisolone, 17 (77 per cent) of 22 patients receiving dexamethasone, and 11 (69 per cent) of 16 controls in the hospital died. We conclude that corticosteroids do not improve the overall survival of patients with severe, late septic shock but may be helpful early in the course and in certain subgroups of patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6384785     DOI: 10.1056/NEJM198411013111801

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  124 in total

Review 1.  Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics?

Authors:  J Briegel
Journal:  Intensive Care Med       Date:  2000-12       Impact factor: 17.440

Review 2.  Pulse corticosteroid therapy with methylprednisolone or dexamethasone.

Authors:  P Hari; R N Srivastava
Journal:  Indian J Pediatr       Date:  1998 Jul-Aug       Impact factor: 1.967

Review 3.  [Cortisone substitution in sepsis. Is less more?].

Authors:  J Briegel
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 4.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.

Authors:  Djillali Annane; Eric Bellissant; Pierre Edouard Bollaert; Josef Briegel; Didier Keh; Yizhak Kupfer
Journal:  BMJ       Date:  2004-08-02

Review 5.  [Corticosteroid administration for acute respiratory distress syndrome : therapeutic option?].

Authors:  P Möhnle; J Briegel
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

Review 6.  Adrenal insufficiency: etiology, diagnosis and treatment.

Authors:  Nicola Neary; Lynnette Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

7.  In-vivo blockage of neutrophil migration by LPS is mimicked by a factor released from LPS-stimulated macrophages.

Authors:  F Q Cunha; G E Souza; C A Souza; B C Cerqueira; S H Ferreira
Journal:  Br J Exp Pathol       Date:  1989-02

8.  Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia.

Authors:  K C Shashidhara; K A Sudharshan Murthy; H Basavana Gowdappa; Abhijith Bhograj
Journal:  J Clin Diagn Res       Date:  2013-07-01

9.  Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X.

Authors:  R L Danner; K A Joiner; J E Parrillo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

10.  Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.

Authors:  J Sörensen; B Kald; C Tagesson; M Lindahl
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.